5.75 easy fill? You should really short ECYT from current level. I'll be interested to know how well that turns out :-)
was to sell 5M shares when the stock price was over $20. Which was exactly what ECYT did. Unfortunately, the management was to busy unloading their own shares to care.
Sorry, no dice. You need to prove **criminal intent** on the part of ECYT management for your lawsuit to stick, not mere bad judgment. 99.99% lawsuits filed after a big drop in stock price end up dismissed, if you're a stockholder, you're odds of covering any money this way is nearly zero.
What is my point? My point is often time analysts don't know jack about which way FDA is going to swing, and investors shouldn't get suckered into these lofty pie-in-the-sky price targets that are based on nothing by wild speculations. The disaster with CYTK is just the latest reminder.
Sorry, judging by the absolute zero support in the price action, very few actually gives credence to these fluffy price targets pulled out of you know where.
I was just reading some of the glowing recommendations from JMP, Roth and Piper on CYTK issued 1-3 days ago. The breathless excitement was overwhelming. One can easily draw the parallel between this and Dr. Schimmer's unbridled optimism.
Here are some snippets for your enjoyment:
Cytokinetics risk/reward attractive ahead of data, says JMP Securities
JMP Securities thinks that the upcoming data for Cytokinetics' tirasemtiv for ALS could be transformative. The firm believes that the stock could more than double on clearly positive results and drop about 50% on negative results. The firm reiterates a $23 price target and Outperform rating on the shares.
Cytokinetics should be owned ahead of data, says Roth Capital
Roth Capital recommends that investors own Cytokinetics ahead of data expected to be unveiled on April 29. The firm thinks the data could be "a transformational event" for the company, and reiterates a $25 price target and Buy rating on the shares.
Cytokinetics mentioned positively at Piper Jaffray
Shares are Overweight rated with a $18 price target.
CYTK tanked more than 60% today. Just 3 days ago, 3 analysts, including our very own Piper Jaffray recommended that CYTK should be bough ahead of FDA decision. Curiously, the very same Piper is recommending the same for INSM.
Pumper's Dr. Schemmer, that's something you can bank on, right?
If this company is doing this badly when American economy and stock market are rallying, I don't think there is much hope left. This is much more than a stock getting caught in a cyclic downturn, much of the lost demand is gone for good, IMHO.
YGE's management is clearly subpar, but the potential for solar is simply enormous in China and beyond. Hopefully, as one of the top solar makers in China that enjoys unwavering backing from the government, YGE would benefit from the rising tide of demand and become profitable ASAP. When that happens, this can be easily a multi-bagger from here.
With all due respect, BAC and DB all have new PT much higher than the current price. Sure it sux to be a laggard, but the management has plotted a path to profitability which many reputable experts find to be credible. What we see today is just volatility which is nothing new to Chinese solar, least of which YGE, which has a history of wild movements between 5 and 7.
Mar 20, 2014
Solarbuzz: Solar PV industry set to grow rapidly in next 5 years, DigiTimes says
The solar photovoltaic industry is set for rapid growth for the next five years with a projected increase in annual PV module revenue to $50B by 2018, reports DigiTimes, citing Solarbuzz. The global solar PV industry is set to reach a capacity level of 500 MW in 2018 and up to 100GW of annual deployment in 2018. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE).
Unfortunately, the existing finance agreement will expire before the parliament reconvenes. I'm sure there will be additional cost to get the bankers to agree to another round of financing package, given the added headaches from dealing with GOM, and the fact that price of copper is much lower today than it was when the last finance agreement was worked out.